Affimed to Present Data on AFM13 at the 15th International Conference on Malignant Lymphoma in Lugano, Switzerland

Poster Presentation:

Abstract: Clinical and Biological Evaluation of the Novel CD30/CD16A Tetravalent Bispecific Antibody (AFM13) in Relapsed or Refractory CD30-Positive Lymphoma with Cutaneous Presentation: A Biomarker Phase Ib/IIa Study (NCT03192202)
Section: Immunotherapy
Poster sessions: Wednesday, June 19, 12:00 – 17:00 (CET), Thursday, June 20, 9:00 – 17:00 (CET) and Friday, June 21, 9:00 – 18:30 (CET)
Location: Marquee Parco Ciani

A. Sawas et al. poster

Oral Presentation:

Abstract: Investigating safety and preliminary efficacy of AFM13 plus Pembrolizumab in Patients with Relapsed/Refractory Hodgkin Lymphoma after Brentuximab Vedotin Failure
Session: 11 – New Drugs Combination
Date and Time: Saturday, June 22, 8:30 – 10:00 am (CET)
Location: Room A (main hall of Palazzo dei Congressi)

S. Ansell oral presentation

We use cookies to give you the best experience on our website. By continuing to use it, you agree with it.

Okay